By: IPP Bureau
Last updated : May 22, 2026 6:13 pm
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Lupin Limited has received approval from China’s National Medical Products Administration for its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate for Oral Suspension, marking the company’s first product entry into the Chinese pharmaceutical market.
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment.
The product, Oseltamivir Phosphate for oral suspension, 6 mg/mL, is indicated for the treatment and prevention of influenza A and B, including paediatric use.
The development represents a strategic milestone in Lupin’s global expansion plans and strengthens its presence in one of the world’s largest pharmaceutical markets. The company said the partnership aims to improve access to affordable and high-quality influenza therapies, particularly for children.
Fabrice Egros, President – Corporate Development at Lupin, said the approval reflects the company’s commitment to expanding access to critical therapies in China through strategic collaborations.
Wei Ren, President of Yabao Pharmaceuticals, added that the approval reinforces the company’s focus on paediatric healthcare and highlights the strength of its partnership with Lupin, while also paving the way for future expansion in chronic disease and paediatric drug development.